



Figure E9 (A) Sensitivity analysis of immunological parameters in severe and non-severe patients of COVID-19


(1) IL-1 β




(2) IL-2




(3) IL-4




(4) IL-8




(5) IL-18




(6) IL-1Ra



(7) IL-2R



(8) IL-6



(9) IFN- γ






Figure E9 (A) (Continued)


(10) TNF- α




(11) IL-10




(12) CD3+T(ab)




(13) CD3+T(%)



(14) CD4+T(ab)



(15) CD4+T(%)



(16) CD8+T(%)






Figure E9 (A) (Continued)


(17) CD8+T(ab)




(18) CD4+T/CD8+T ratio




(19) B cell(ab)




(20) IgG




(21) NK cell(ab)




(22) C3




(23) C4



(24) IgA



(25) IgM



(26) IgE






Figure E9 (B) Sensitivity analysis of immunological parameters non-survivors and survivors of COVID-19


(1) CD3+T(ab)




(2) CD3+T(%)




(3) CD4+T(ab)




(4) CD4+T(%)




(5) CD8+T(ab)




(6) CD8+T(%)




(7) CD4+T/CD8+T ratio




(8) B cell(ab)




(9) NK cell(ab)




(10) IL-1β




(11) IL-2




(12) IL-2R




(18) IL-8




(13) IL-4




(19) IL-10




(14) IL-6




(20) TNF-α




(15) IFN-γ




(21) IgA




(16) IgM



(22) IgG



(17) C3



(23) C4

